On July 30, 2026, 60 Degrees Pharmaceuticals entered into a Securities Purchase Agreement for a private placement closing on July 31, 2026. The company issued approximately $1.0 million in gross proceeds by selling 191,571 shares of common stock and pre-funded warrants to purchase 383,142 shares at $1.74 per share. The offering included Series A and B warrants to purchase up to 574,413 shares each, exercisable at $1.49 per share with expiration periods of five years and twenty-four months respectively. Proceeds will fund working capital, general operations, and research and development. H.C. Wainwright & Co. served as the exclusive placement agent. The company operates in the pharmaceutical industry, developing and commercializing medicines for vector-borne diseases.
